Rilotumumab Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Rilotumumab is an anti-HGF antibody that prevents ligand binding to MET and its activation.
Clinical Use
A phase I/II trial of rilotumumab in combination with erlotinib was evaluated in previously treated NSCLC patients with metastatic disease. The results indicated a favorable safety profile and success in terms of disease control rate. A phase Ib/II trial of rilotumumab or ganitumab in combination with etoposide and carboplatin or cisplatin was evaluated in extensive-stage SCLC patients.
Rilotumumab Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
